SFI
AVTX icon

Susquehanna Fundamental Investments’s Avalo Therapeutics AVTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8
Closed -$74K – 1697
2021
Q2 		$74K Sell
8
-29
-78% -$243K ﹤0.01% 1596
2021
Q1 		$320K Buy
37
+15
+68% +$142K 0.01% 1276
2020
Q4 		$164K Sell
22
-5
-19% -$34.7K ﹤0.01% 1383
2020
Q3 		$180K Buy
27
+14
+108% +$105K 0.01% 1214
2020
Q2 		$94K Buy
+13
New +$94.4K ﹤0.01% 909

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna Fundamental Investments's AVTX Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Avalo Therapeutics (AVTX) in Q3 2021, closing a stake of 8 shares — an estimated $74K sold.

Susquehanna Fundamental Investments first reported a position in AVTX in Q2 2020 and held it in 5 quarters. The position peaked at $320K in Q1 2021. 71 funds tracked by Wall St. Rank hold AVTX as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining Avalo Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 8 Avalo Therapeutics shares in Q3 2021, an estimated $74K.
  • Susquehanna Fundamental Investments first reported a position in Avalo Therapeutics in Q2 2020 and held it in 5 quarters.
  • Susquehanna Fundamental Investments's Avalo Therapeutics position peaked at $320K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.